modelC1InhibitorPlasmaDerived

Diagram of C1InhibitorPlasmaDerived

Extends from Pharmacolibrary.Drugs.ATC.B.B06AC01.

Information

name:C1InhibitorPlasmaDerived
ATC code:B06AC01
route:intravenous
compartments:2
dosage:1000mg
volume of distribution:3L
clearance:1.64L/h
other parameters in model implementation

C1-inhibitor (C1-INH), plasma derived, is a purified human plasma protein that inhibits activated C1 complex, and is used for the treatment and prevention of hereditary angioedema (HAE) attacks. It is approved and marketed for acute and prophylactic management of HAE in both adults and children.

Pharmacokinetics

Pharmacokinetics in adults with hereditary angioedema, both male and female, after intravenous administration of 1000 U (approx 12.5 mg/kg) of human plasma-derived C1-inhibitor (Berinert, Cinryze); based on published clinical study data.

References

  1. Pawaskar, D, et al., & Sidhu, J (2018). Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 48(10) 1325–1332. DOI:10.1111/cea.13220 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29998524

  2. Goggs, R, & Behling-Kelly, E (2019). C. BMC veterinary research 15(1) 475–None. DOI:10.1186/s12917-019-2220-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31888626

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)